Ocugen Inc OCGN.OQ OCGN.O is expected to show a rise in quarterly revenue when it reports results on March 4 for the period ending December 31 2025
The Malvern Pennsylvania-based company is expected to report a 12.6% increase in revenue to $860 thousand from $764 thousand a year ago, according to the mean estimate from 5 analysts, based on LSEG data.
LSEG's mean analyst estimate for Ocugen Inc is for a loss of 6 cents per share.
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 5 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."
The mean earnings estimate of analysts was unchanged in the last three months.
Wall Street's median 12-month price target for Ocugen Inc is $8.00, about 339.6% above its last closing price of $1.82
Previous quarterly performance (using preferred earnings measure in US dollars).
QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
Sep. 30 2025 | -0.05 | -0.06 | -0.07 | Missed | -25 |
Jun. 30 2025 | -0.06 | -0.06 | -0.05 | Beat | 13 |
Mar. 31 2025 | -0.05 | -0.06 | -0.05 | Beat | 13 |
Dec. 31 2024 | -0.04 | -0.05 | -0.05 | Met | 4.8 |
Sep. 30 2024 | -0.06 | -0.05 | -0.05 | Met | 6.2 |
Jun. 30 2024 | -0.05 | -0.05 | -0.04 | Beat | 25 |
Mar. 31 2024 | -0.06 | -0.06 | -0.05 | Beat | 21 |
Dec. 31 2023 | -0.06 | -0.03 | Beat | 53.8 |
This summary was machine generated March 2 at 13:39 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)